Nanocarrier Co. Ltd., of Chiba, Japan, submitted an investigational new drug application to the Pharmaceuticals and Medical Devices Agency in Japan for the phase III clinical trial of NC-6004 in patients with locally advanced or metastatic pancreatic cancer. The drug consists of micellar nanoparticles containing cisplatin derivatives.